View ValuationIntegrated Diagnostics Holdings 향후 성장Future 기준 점검 4/6Integrated Diagnostics Holdings (는) 각각 연간 17.9% 및 15.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 17.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 35.3% 로 예상됩니다.핵심 정보17.9%이익 성장률17.87%EPS 성장률Healthcare 이익 성장17.3%매출 성장률15.9%향후 자기자본이익률35.34%애널리스트 커버리지Low마지막 업데이트10 May 2026최근 향후 성장 업데이트공고 • Sep 04Integrated Diagnostics Holdings plc Provides Earnings Guidance for the Full Year 2025Integrated Diagnostics Holdings plc provided earnings guidance for the full year 2025. for the year, the company expects revenue growth coming in above 30%.공고 • Sep 01Integrated Diagnostics Holdings Reaffirms Revenue Guidance for the Fiscal Year 2023Integrated Diagnostics Holdings reaffirmed revenue guidance for the fiscal year 2023. Considering their strong first half results, the solid strategies in place, and the positive momentum enjoyed by the Egyptian and Jordian subsidiaries, the company reaffirms their guidance of full-year conventional revenue (excluding Covid-19-related contributions) year-on-year growth of around 30% for fiscal year 2023.모든 업데이트 보기Recent updates공고 • Jun 25Moamena Abdul Wahab Kamel and Hend El Sherbini of Integrated Diagnostics Holdings plc acquired an additional 21.67% stake in Integrated Diagnostics Holdings plc (LSE:IDHC) from Actis LLP for $63 million.Moamena Abdul Wahab Kamel and Hend El Sherbini of Integrated Diagnostics Holdings plc acquired an additional 21.67% stake in Integrated Diagnostics Holdings plc (LSE:IDHC) from Actis LLP for $63 million on June 22, 2026. A cash consideration valued at $0.5 per share will be paid by the buyer. As part of consideration, an undisclosed value is paid towards common equity of Integrated Diagnostics Holdings plc.The Elliott Transaction and the Offer has been financed by (i) a loan made byRNAFIII Cooperatief U.A. and RMBV2 (together, "RMBV") to Bidcoin the amount of up to $60 million (the "RMBV Loan"); and (ii) equity subscriptions to be made by Hend El Sherbini and Moamena Abdul Wahab Kamel in an amount of not less than $43 million and not more than $150 million. The Elliott Transaction was financed by a $20 million drawdown from the RMBV Loan; and equity subscriptions made by Hend El Sherbini and Moamena Abdul Wahab Kamel in an amount of $43 million. Bidco does not intend to effect any material change with regard to: (i) the headcount of IDH's employees and managers and (ii) the conditions of employment or balance of skills and functions of the management or employees of IDH. In a related transaction Moamena Abdul Wahab Kamel and Hend El Sherbini will acquire all the remaining stake of Integrated Diagnostics Holdings plc. Stuart Andrews and Harry Rees of Canaccord Genuity Limited acted as financial advisor for Moamena Abdul Wahab Kamel and Hend El Sherbini. James Thompson, Hani Nassef, Ben Wilkinson, Tom Quincey and Lamyaa Gadelhak of Baker & McKenzie LLP acted as legal advisor for Moamena Abdul Wahab Kamel and Hend El Sherbini. Moamena Abdul Wahab Kamel and Hend El Sherbini of Integrated Diagnostics Holdings plc completed the acquisition of an additional 21.67% stake in Integrated Diagnostics Holdings plc (LSE:IDHC) from Actis LLP on June 22, 2026.공고 • May 22Integrated Diagnostics Holdings plc Approves Final Dividend for the Year Ended 31 December 2025Integrated Diagnostics Holdings plc at its Annual General Meeting held on May 19, 2026 approved to declare a final dividend of USD 0.0085 per Share in respect of the year ended 31 December 2025.공고 • May 21Integrated Diagnostics Holdings plc to Report Q1, 2026 Results on May 20, 2026Integrated Diagnostics Holdings plc announced that they will report Q1, 2026 results on May 20, 2026공고 • May 20Integrated Diagnostics Holdings plc to Report Q1, 2026 Results on May 25, 2026Integrated Diagnostics Holdings plc announced that they will report Q1, 2026 results on May 25, 2026공고 • Apr 21Integrated Diagnostics Holdings plc, Annual General Meeting, May 19, 2026Integrated Diagnostics Holdings plc, Annual General Meeting, May 19, 2026. Location: strand hanson ltd, 26 mount row, mayfair, w1k 3sq, london United Kingdom공고 • Apr 19Integrated Diagnostics Holdings plc Recommends Cash Dividend for the Year Ended December 31, 2025 , Payable on June 22, 2026Integrated Diagnostics Holdings plc recommended that a cash dividend of USD 4.9 million (USD 0.0085 per share), for the year ended December 31, 2025, should be paid to shareholders who appear on the register as of 29 May 2026, with an ex-dividend date of 28 May 2026. The payment date for the dividend will be 22 June 2026. Proposed dividends for ordinary shares are subject to the approval of the Annual General Meeting (AGM) and are not recognised as a liability as of 31 December 2025.공고 • Nov 07Integrated Diagnostics Holdings plc to Report Nine Months, 2025 Results on Nov 13, 2025Integrated Diagnostics Holdings plc announced that they will report nine months, 2025 results on Nov 13, 2025공고 • Sep 04Integrated Diagnostics Holdings plc Provides Earnings Guidance for the Full Year 2025Integrated Diagnostics Holdings plc provided earnings guidance for the full year 2025. for the year, the company expects revenue growth coming in above 30%.공고 • Aug 29Integrated Diagnostics Holdings plc to Report Q2, 2025 Results on Sep 02, 2025Integrated Diagnostics Holdings plc announced that they will report Q2, 2025 results at 6:00 AM, Coordinated Universal Time on Sep 02, 2025공고 • May 22Integrated Diagnostics Holdings plc to Report Q1, 2025 Results on May 28, 2025Integrated Diagnostics Holdings plc announced that they will report Q1, 2025 results at 6:00 AM, Coordinated Universal Time on May 28, 2025공고 • Apr 25Integrated Diagnostics Holdings plc, Annual General Meeting, May 27, 2025Integrated Diagnostics Holdings plc, Annual General Meeting, May 27, 2025. Location: 2 more london riverside, se1 2jt, london United Kingdom공고 • Apr 10Integrated Diagnostics Holdings plc to Report Fiscal Year 2024 Results on Apr 17, 2025Integrated Diagnostics Holdings plc announced that they will report fiscal year 2024 results at 6:00 AM, Coordinated Universal Time on Apr 17, 2025공고 • Nov 12Integrated Diagnostics Holdings plc to Report Nine Months, 2024 Results on Nov 14, 2024Integrated Diagnostics Holdings plc announced that they will report nine months, 2024 results on Nov 14, 2024공고 • Sep 05Integrated Diagnostics Announces Completion of the Egyptian Exchange DelistingIntegrated Diagnostics Holdings plc refers to: the shareholder resolutions passed at the Company's Extraordinary General Meetings held on 12 June 2024 and 18 July 2024 approving, amongst other things, the voluntary delisting (the ‘EGX Delisting’) of the Company's ordinary shares (the ‘Shares’) from the Egyptian Exchange (the ‘EGX’) and the Company's repurchase of Shares from the beneficial owners of the Shares that were traded on the EGX and held by Misr for Central Clearing, Depository and Registry (‘MCDR’) (‘EGX Shares’)if so required by such beneficial owners during the relevant period; the Company's announcement on 13 August 2024 in relation to the timeline for the share buyback under the EGX's special operations market (OPR); and the Company's announcement on 27 August 2024 in relation to the share buyback under the EGX's special operations market (OPR). Further to the Company's repurchase of 18,673,728 EGX Shares on 26 August 2024 pursuant to the share buyback under the EGX's special operations market (OPR), the EGX's Listing Committee has, on 4 September 2024, published its formal decision to delist the Shares from the EGX. As a result, the Company's listing information has been removed from the EGX's database, effective as at the commencement of the trading session on 5 September 2024. Accordingly, the EGX Delisting has become effective and completed on 4 September 2024, and the last trading date of the Shares on the EGX was 4 September 2024. The Shares remain admitted to the equity shares (transition) category (previously, the standard listing segment) of the Official List of the UK Financial Conduct Authority and admitted to trading on the main market for listed securities of the London Stock Exchange (the ‘LSE’), which is now the sole listing venue of the Company. Following the completion of the EGX Delisting, all remaining EGX Shares that were not validly tendered into the EGX's special operations market (OPR) and repurchased by the Company pursuant to the share buyback are no longer capable of being traded on the EGX (such EGX Shares, the ‘Remaining Shares’).공고 • May 29Integrated Diagnostics Holdings plc to Report Q1, 2024 Results on May 30, 2024Integrated Diagnostics Holdings plc announced that they will report Q1, 2024 results at 6:00 AM, Coordinated Universal Time on May 30, 2024공고 • May 03Integrated Diagnostics Holdings plc, Annual General Meeting, May 29, 2024Integrated Diagnostics Holdings plc, Annual General Meeting, May 29, 2024, at 14:00 Coordinated Universal Time. Location: 2 More London Riverside, London, SE1 2JT London United Kingdom Agenda: To receive and consider the Company’s Audited Financial Statements, together with the Reports of the Directors and the Auditor for the year ended 31 December 2023; to consider Lord Anthony Tudor St John, who retires as a director and, being eligible, offers himself for re-election at the AGM, be re-elected; to consider Dr. Hend El-Sherbini, who retires as a director and, being eligible, offers herself for re-election at the AGM, be re-elected; and to consider other matters of business.공고 • Jan 19+ 1 more updateIntegrated Diagnostics Holdings Appoints Sherif El Zeiny as Group Chief Financial OfficerIntegrated Diagnostics Holdings announced the appointment of Sherif El Zeiny as Group Chief Financial Officer, effective 18 January 2024. El Zeiny is a seasoned and certified Board Director and Executive Partner, boasting over three decades of experience in financial management, business leadership, and corporate strategy. Previously, El Zeiny served as Vice President and Group Chief Financial Officer at Elsewedy Electric.공고 • Sep 01Integrated Diagnostics Holdings Reaffirms Revenue Guidance for the Fiscal Year 2023Integrated Diagnostics Holdings reaffirmed revenue guidance for the fiscal year 2023. Considering their strong first half results, the solid strategies in place, and the positive momentum enjoyed by the Egyptian and Jordian subsidiaries, the company reaffirms their guidance of full-year conventional revenue (excluding Covid-19-related contributions) year-on-year growth of around 30% for fiscal year 2023.공고 • Aug 31Integrated Diagnostics Holdings plc to Report First Half, 2023 Results on Aug 31, 2023Integrated Diagnostics Holdings plc announced that they will report first half, 2023 results on Aug 31, 2023공고 • Jun 22+ 1 more updateIntegrated Diagnostics Holdings plc Appoints Sherif El Etreby as Group Strategic Investment Officer, Effective 15 August 2023Integrated Diagnostics Holdings plc announced the appointment of Sherif El Etreby, who will fill the role of Group Strategic Investment Officer, effective 15 August 2023. El Etreby, filling the new role of Group Strategic Investment Officer, will be responsible for developing and directing the Group's strategy pillars and long-term outlook, identifying potential opportunities for business expansion. This new position was created in line with IDH's continuous efforts to identify and maximise long-term growth across its current and potential markets. El Etreby is a seasoned financial executive with over 25 years of experience in the financial field, boasting several significant roles and major achievements in banking institutions for 10 years. He currently serves as the Senior Vice President of Investments at Egyptian Industrial Investment Group. El Etreby's previous experiences include nine years as the Senior Planning Executive at Egyptian Steel Group, as well as a member of the founding team of Egyptian Cement Company during the same period. Prior to those roles, he served as the Regional Controller for Special Projects - Middle East and Africa at Lafarge, as well as Deputy Regional Business Controller for North Africa and Head of Planning at Orascom Construction - Cement Sector. He has been involved in major syndication loans facilities, acquisitions, and divestments in the cement and steel sectors in the Middle East and Africa, including the acquisition of Lafarge to Orascom Construction Industries - Cement Sector in 2008. He was also involved in the sell down of the founder's stack in Egyptian Steel Group to Al Ezz Dekheila Steel Co. in 2021.공고 • May 05Integrated Diagnostics Holdings plc, Annual General Meeting, May 30, 2023Integrated Diagnostics Holdings plc, Annual General Meeting, May 30, 2023, at 14:00 Coordinated Universal Time. Location: 2 More London Riverside, London, SE1 2JT London United Kingdom Agenda: To consider the Company's Audited Financial Statements, together with the Reports of the Directors and the Auditor for the year ended 31 December 2022; to consider Lord Anthony Tudor St John, who retires as a director and, being eligible, offers himself for re-election at the AGM, be re-elected; to consider Dan Johan Wilmar Olsson, who retires as a director and, being eligible, offers himself for re-election at the AGM, be re-elected; to consider Hussein Hassan Choucri, who retires as a director and, being eligible, offers himself for re-election at the AGM, be re-elected; to consider Yvonne Stillhart, who retires as a director and, being eligible, offers herself for re-election; to consider re-appoint PricewaterhouseCoopers LLP as Auditor; and to consider other matters.공고 • Feb 01Integrated Diagnostics Holdings to No Longer Pursue Acquisition of IDC StakeIntegrated Diagnostics Holdings plc (LSE:IDHC) announced that it will no longer pursue negotiations for the acquisition of a 50% stake in Islamabad Diagnostic Center ("IDC"). The Group has notified Evercare IGA Holdings Limited (a company managed by TPG Inc., the "Seller") of its decision which comes at the end of an eighteen-month process that saw the parties work closely together to bring the transaction to completion. While the original share purchase agreement (the "SPA"), which had been signed on 20 December 2021, expired on 29 August 2022, IDH and the Seller continued negotiations aimed at concluding a transaction on modified terms. Despite the efforts of the parties, extensive delays in the regulatory review process, the challenging global economic environment and the condition precedent related to repatriating funds, have resulted in the discontinuation of negotiations towards completing the transaction. As always, IDH continues to assess potential value-accretive acquisition opportunities in new markets across Africa, the Middle East, and Asia where it feels its business model is best-suited to capitalise on healthcare and consumer trends similar to those prevailing in our current markets of operation.이익 및 매출 성장 예측OTCPK:IDGX.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (EGP Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202812,9922,328N/AN/A112/31/202711,6611,994N/AN/A112/31/20269,8171,590N/AN/A13/31/20268,3451,454N/AN/AN/A12/31/20257,8551,2621,3831,904N/A9/30/20257,3951,317N/AN/AN/A6/30/20256,7651,0971,1591,507N/A3/31/20256,132920N/AN/AN/A12/31/20245,7201,0771,3441,569N/A9/30/20245,176847N/AN/AN/A6/30/20244,748817607839N/A3/31/20244,378755265559N/A12/31/20234,123510218544N/A9/30/20233,858538190514N/A6/30/20233,5233425335N/A3/31/20233,340417-362-1N/A12/31/20223,605541-100209N/A9/30/20224,258716417700N/A6/30/20224,8861,1881,1171,438N/A3/31/20225,2761,3831,8242,091N/A12/31/20215,2251,4132,0062,270N/A9/30/20214,7531,3221,9232,153N/A6/30/20214,0001,0621,4461,600N/A3/31/20213,286816N/AN/AN/A12/31/20202,656594757883N/A9/30/20202,247523N/AN/AN/A6/30/20202,115466452621N/A3/31/20202,180491N/AN/AN/A12/31/20192,226511N/A697N/A9/30/20192,193508N/AN/AN/A6/30/20192,117510N/A621N/A3/31/20192,035518N/AN/AN/A12/31/20181,921502N/A556N/A9/30/20181,790447N/AN/AN/A6/30/20181,695435N/A434N/A3/31/20181,605405N/A418N/A12/31/20171,514374N/A403N/A9/30/20171,425343N/AN/AN/A6/30/20171,303292N/A416N/A3/31/20171,237276N/A407N/A12/31/20161,171260N/A399N/A9/30/20161,116247N/AN/AN/A6/30/20161,074251N/A311N/A3/31/20161,044198N/A250N/A12/31/20151,015145N/A190N/A9/30/2015980134N/AN/AN/A더 보기애널리스트 향후 성장 전망수입 대 저축률: IDGX.F 의 연간 예상 수익 증가율(17.9%)이 saving rate(3.7%)보다 높습니다.수익 vs 시장: IDGX.F 의 연간 수익(17.9%)이 US 시장(16.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: IDGX.F 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: IDGX.F 의 수익(연간 15.9%)이 US 시장(연간 12.9%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: IDGX.F 의 수익(연간 15.9%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: IDGX.F의 자본 수익률은 3년 후 35.3%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/11 06:03종가2026/07/28 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Integrated Diagnostics Holdings plc는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Marc HammoudDeutsche BankAhmed MoatazEFG-Hermes ResearchRaj SinhaHSBC1명의 분석가 더 보기
공고 • Sep 04Integrated Diagnostics Holdings plc Provides Earnings Guidance for the Full Year 2025Integrated Diagnostics Holdings plc provided earnings guidance for the full year 2025. for the year, the company expects revenue growth coming in above 30%.
공고 • Sep 01Integrated Diagnostics Holdings Reaffirms Revenue Guidance for the Fiscal Year 2023Integrated Diagnostics Holdings reaffirmed revenue guidance for the fiscal year 2023. Considering their strong first half results, the solid strategies in place, and the positive momentum enjoyed by the Egyptian and Jordian subsidiaries, the company reaffirms their guidance of full-year conventional revenue (excluding Covid-19-related contributions) year-on-year growth of around 30% for fiscal year 2023.
공고 • Jun 25Moamena Abdul Wahab Kamel and Hend El Sherbini of Integrated Diagnostics Holdings plc acquired an additional 21.67% stake in Integrated Diagnostics Holdings plc (LSE:IDHC) from Actis LLP for $63 million.Moamena Abdul Wahab Kamel and Hend El Sherbini of Integrated Diagnostics Holdings plc acquired an additional 21.67% stake in Integrated Diagnostics Holdings plc (LSE:IDHC) from Actis LLP for $63 million on June 22, 2026. A cash consideration valued at $0.5 per share will be paid by the buyer. As part of consideration, an undisclosed value is paid towards common equity of Integrated Diagnostics Holdings plc.The Elliott Transaction and the Offer has been financed by (i) a loan made byRNAFIII Cooperatief U.A. and RMBV2 (together, "RMBV") to Bidcoin the amount of up to $60 million (the "RMBV Loan"); and (ii) equity subscriptions to be made by Hend El Sherbini and Moamena Abdul Wahab Kamel in an amount of not less than $43 million and not more than $150 million. The Elliott Transaction was financed by a $20 million drawdown from the RMBV Loan; and equity subscriptions made by Hend El Sherbini and Moamena Abdul Wahab Kamel in an amount of $43 million. Bidco does not intend to effect any material change with regard to: (i) the headcount of IDH's employees and managers and (ii) the conditions of employment or balance of skills and functions of the management or employees of IDH. In a related transaction Moamena Abdul Wahab Kamel and Hend El Sherbini will acquire all the remaining stake of Integrated Diagnostics Holdings plc. Stuart Andrews and Harry Rees of Canaccord Genuity Limited acted as financial advisor for Moamena Abdul Wahab Kamel and Hend El Sherbini. James Thompson, Hani Nassef, Ben Wilkinson, Tom Quincey and Lamyaa Gadelhak of Baker & McKenzie LLP acted as legal advisor for Moamena Abdul Wahab Kamel and Hend El Sherbini. Moamena Abdul Wahab Kamel and Hend El Sherbini of Integrated Diagnostics Holdings plc completed the acquisition of an additional 21.67% stake in Integrated Diagnostics Holdings plc (LSE:IDHC) from Actis LLP on June 22, 2026.
공고 • May 22Integrated Diagnostics Holdings plc Approves Final Dividend for the Year Ended 31 December 2025Integrated Diagnostics Holdings plc at its Annual General Meeting held on May 19, 2026 approved to declare a final dividend of USD 0.0085 per Share in respect of the year ended 31 December 2025.
공고 • May 21Integrated Diagnostics Holdings plc to Report Q1, 2026 Results on May 20, 2026Integrated Diagnostics Holdings plc announced that they will report Q1, 2026 results on May 20, 2026
공고 • May 20Integrated Diagnostics Holdings plc to Report Q1, 2026 Results on May 25, 2026Integrated Diagnostics Holdings plc announced that they will report Q1, 2026 results on May 25, 2026
공고 • Apr 21Integrated Diagnostics Holdings plc, Annual General Meeting, May 19, 2026Integrated Diagnostics Holdings plc, Annual General Meeting, May 19, 2026. Location: strand hanson ltd, 26 mount row, mayfair, w1k 3sq, london United Kingdom
공고 • Apr 19Integrated Diagnostics Holdings plc Recommends Cash Dividend for the Year Ended December 31, 2025 , Payable on June 22, 2026Integrated Diagnostics Holdings plc recommended that a cash dividend of USD 4.9 million (USD 0.0085 per share), for the year ended December 31, 2025, should be paid to shareholders who appear on the register as of 29 May 2026, with an ex-dividend date of 28 May 2026. The payment date for the dividend will be 22 June 2026. Proposed dividends for ordinary shares are subject to the approval of the Annual General Meeting (AGM) and are not recognised as a liability as of 31 December 2025.
공고 • Nov 07Integrated Diagnostics Holdings plc to Report Nine Months, 2025 Results on Nov 13, 2025Integrated Diagnostics Holdings plc announced that they will report nine months, 2025 results on Nov 13, 2025
공고 • Sep 04Integrated Diagnostics Holdings plc Provides Earnings Guidance for the Full Year 2025Integrated Diagnostics Holdings plc provided earnings guidance for the full year 2025. for the year, the company expects revenue growth coming in above 30%.
공고 • Aug 29Integrated Diagnostics Holdings plc to Report Q2, 2025 Results on Sep 02, 2025Integrated Diagnostics Holdings plc announced that they will report Q2, 2025 results at 6:00 AM, Coordinated Universal Time on Sep 02, 2025
공고 • May 22Integrated Diagnostics Holdings plc to Report Q1, 2025 Results on May 28, 2025Integrated Diagnostics Holdings plc announced that they will report Q1, 2025 results at 6:00 AM, Coordinated Universal Time on May 28, 2025
공고 • Apr 25Integrated Diagnostics Holdings plc, Annual General Meeting, May 27, 2025Integrated Diagnostics Holdings plc, Annual General Meeting, May 27, 2025. Location: 2 more london riverside, se1 2jt, london United Kingdom
공고 • Apr 10Integrated Diagnostics Holdings plc to Report Fiscal Year 2024 Results on Apr 17, 2025Integrated Diagnostics Holdings plc announced that they will report fiscal year 2024 results at 6:00 AM, Coordinated Universal Time on Apr 17, 2025
공고 • Nov 12Integrated Diagnostics Holdings plc to Report Nine Months, 2024 Results on Nov 14, 2024Integrated Diagnostics Holdings plc announced that they will report nine months, 2024 results on Nov 14, 2024
공고 • Sep 05Integrated Diagnostics Announces Completion of the Egyptian Exchange DelistingIntegrated Diagnostics Holdings plc refers to: the shareholder resolutions passed at the Company's Extraordinary General Meetings held on 12 June 2024 and 18 July 2024 approving, amongst other things, the voluntary delisting (the ‘EGX Delisting’) of the Company's ordinary shares (the ‘Shares’) from the Egyptian Exchange (the ‘EGX’) and the Company's repurchase of Shares from the beneficial owners of the Shares that were traded on the EGX and held by Misr for Central Clearing, Depository and Registry (‘MCDR’) (‘EGX Shares’)if so required by such beneficial owners during the relevant period; the Company's announcement on 13 August 2024 in relation to the timeline for the share buyback under the EGX's special operations market (OPR); and the Company's announcement on 27 August 2024 in relation to the share buyback under the EGX's special operations market (OPR). Further to the Company's repurchase of 18,673,728 EGX Shares on 26 August 2024 pursuant to the share buyback under the EGX's special operations market (OPR), the EGX's Listing Committee has, on 4 September 2024, published its formal decision to delist the Shares from the EGX. As a result, the Company's listing information has been removed from the EGX's database, effective as at the commencement of the trading session on 5 September 2024. Accordingly, the EGX Delisting has become effective and completed on 4 September 2024, and the last trading date of the Shares on the EGX was 4 September 2024. The Shares remain admitted to the equity shares (transition) category (previously, the standard listing segment) of the Official List of the UK Financial Conduct Authority and admitted to trading on the main market for listed securities of the London Stock Exchange (the ‘LSE’), which is now the sole listing venue of the Company. Following the completion of the EGX Delisting, all remaining EGX Shares that were not validly tendered into the EGX's special operations market (OPR) and repurchased by the Company pursuant to the share buyback are no longer capable of being traded on the EGX (such EGX Shares, the ‘Remaining Shares’).
공고 • May 29Integrated Diagnostics Holdings plc to Report Q1, 2024 Results on May 30, 2024Integrated Diagnostics Holdings plc announced that they will report Q1, 2024 results at 6:00 AM, Coordinated Universal Time on May 30, 2024
공고 • May 03Integrated Diagnostics Holdings plc, Annual General Meeting, May 29, 2024Integrated Diagnostics Holdings plc, Annual General Meeting, May 29, 2024, at 14:00 Coordinated Universal Time. Location: 2 More London Riverside, London, SE1 2JT London United Kingdom Agenda: To receive and consider the Company’s Audited Financial Statements, together with the Reports of the Directors and the Auditor for the year ended 31 December 2023; to consider Lord Anthony Tudor St John, who retires as a director and, being eligible, offers himself for re-election at the AGM, be re-elected; to consider Dr. Hend El-Sherbini, who retires as a director and, being eligible, offers herself for re-election at the AGM, be re-elected; and to consider other matters of business.
공고 • Jan 19+ 1 more updateIntegrated Diagnostics Holdings Appoints Sherif El Zeiny as Group Chief Financial OfficerIntegrated Diagnostics Holdings announced the appointment of Sherif El Zeiny as Group Chief Financial Officer, effective 18 January 2024. El Zeiny is a seasoned and certified Board Director and Executive Partner, boasting over three decades of experience in financial management, business leadership, and corporate strategy. Previously, El Zeiny served as Vice President and Group Chief Financial Officer at Elsewedy Electric.
공고 • Sep 01Integrated Diagnostics Holdings Reaffirms Revenue Guidance for the Fiscal Year 2023Integrated Diagnostics Holdings reaffirmed revenue guidance for the fiscal year 2023. Considering their strong first half results, the solid strategies in place, and the positive momentum enjoyed by the Egyptian and Jordian subsidiaries, the company reaffirms their guidance of full-year conventional revenue (excluding Covid-19-related contributions) year-on-year growth of around 30% for fiscal year 2023.
공고 • Aug 31Integrated Diagnostics Holdings plc to Report First Half, 2023 Results on Aug 31, 2023Integrated Diagnostics Holdings plc announced that they will report first half, 2023 results on Aug 31, 2023
공고 • Jun 22+ 1 more updateIntegrated Diagnostics Holdings plc Appoints Sherif El Etreby as Group Strategic Investment Officer, Effective 15 August 2023Integrated Diagnostics Holdings plc announced the appointment of Sherif El Etreby, who will fill the role of Group Strategic Investment Officer, effective 15 August 2023. El Etreby, filling the new role of Group Strategic Investment Officer, will be responsible for developing and directing the Group's strategy pillars and long-term outlook, identifying potential opportunities for business expansion. This new position was created in line with IDH's continuous efforts to identify and maximise long-term growth across its current and potential markets. El Etreby is a seasoned financial executive with over 25 years of experience in the financial field, boasting several significant roles and major achievements in banking institutions for 10 years. He currently serves as the Senior Vice President of Investments at Egyptian Industrial Investment Group. El Etreby's previous experiences include nine years as the Senior Planning Executive at Egyptian Steel Group, as well as a member of the founding team of Egyptian Cement Company during the same period. Prior to those roles, he served as the Regional Controller for Special Projects - Middle East and Africa at Lafarge, as well as Deputy Regional Business Controller for North Africa and Head of Planning at Orascom Construction - Cement Sector. He has been involved in major syndication loans facilities, acquisitions, and divestments in the cement and steel sectors in the Middle East and Africa, including the acquisition of Lafarge to Orascom Construction Industries - Cement Sector in 2008. He was also involved in the sell down of the founder's stack in Egyptian Steel Group to Al Ezz Dekheila Steel Co. in 2021.
공고 • May 05Integrated Diagnostics Holdings plc, Annual General Meeting, May 30, 2023Integrated Diagnostics Holdings plc, Annual General Meeting, May 30, 2023, at 14:00 Coordinated Universal Time. Location: 2 More London Riverside, London, SE1 2JT London United Kingdom Agenda: To consider the Company's Audited Financial Statements, together with the Reports of the Directors and the Auditor for the year ended 31 December 2022; to consider Lord Anthony Tudor St John, who retires as a director and, being eligible, offers himself for re-election at the AGM, be re-elected; to consider Dan Johan Wilmar Olsson, who retires as a director and, being eligible, offers himself for re-election at the AGM, be re-elected; to consider Hussein Hassan Choucri, who retires as a director and, being eligible, offers himself for re-election at the AGM, be re-elected; to consider Yvonne Stillhart, who retires as a director and, being eligible, offers herself for re-election; to consider re-appoint PricewaterhouseCoopers LLP as Auditor; and to consider other matters.
공고 • Feb 01Integrated Diagnostics Holdings to No Longer Pursue Acquisition of IDC StakeIntegrated Diagnostics Holdings plc (LSE:IDHC) announced that it will no longer pursue negotiations for the acquisition of a 50% stake in Islamabad Diagnostic Center ("IDC"). The Group has notified Evercare IGA Holdings Limited (a company managed by TPG Inc., the "Seller") of its decision which comes at the end of an eighteen-month process that saw the parties work closely together to bring the transaction to completion. While the original share purchase agreement (the "SPA"), which had been signed on 20 December 2021, expired on 29 August 2022, IDH and the Seller continued negotiations aimed at concluding a transaction on modified terms. Despite the efforts of the parties, extensive delays in the regulatory review process, the challenging global economic environment and the condition precedent related to repatriating funds, have resulted in the discontinuation of negotiations towards completing the transaction. As always, IDH continues to assess potential value-accretive acquisition opportunities in new markets across Africa, the Middle East, and Asia where it feels its business model is best-suited to capitalise on healthcare and consumer trends similar to those prevailing in our current markets of operation.